Short answer
Zenas BioPharma, Inc. (ZBIO) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Section 2.02 text contains only a forward-incorporation disclaimer.
Zenas BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Section 2.02 text contains only a forward-incorporation disclaimer
- No fiscal-year 2026 operating results, financial figures, or performance metrics disclosed
- Investors must review the referenced exhibit for substantive earnings information
Item 5.02 · Departure/Election of Directors or Officers
- Christy J. Oliger appointed independent Class II director effective September 1, 2026, serving through the 2029 annual meeting
- Board expanded by one seat, increasing governance capacity and committee oversight
- Oliger joins Nominating and Corporate Governance and Science and Technology committees
- Initial equity award: non-qualified option for 37,000 common shares, plus board and committee cash compensation
- No disclosed related-party transactions or selection arrangements; standard indemnification agreement executed
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted obexelimab’s IgG4-RD BLA, with PDUFA action targeted for May 27, 2027, materially advancing potential commercialization
- Phase 3 INDIGO data showed 56% lower flare risk, with 73.2% flare-free versus 45.4% for placebo at Week 52
- Cash, equivalents and investments totaled $673.9M; management expects funding through Q2 2029 assuming $75M milestone and $75M debt draw
- Q2 net loss widened to $111.5M from $52.2M as R&D reached $62.9M and AIPR&D expense totaled $30.0M
- Key catalysts include Q4 2026 SunStone SLE topline data and year-end ZB021 Phase 1 data; CFO transitions September 30 with interim finance leadership
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zenas BioPharma, Inc. 8-K filings
Get the next ZBIO 8-K as it lands
Follow ZBIO for push alerts, or ask the research agent what this filing means.